Transgene SA · EURONEXT:TNG
Transgene SA — Investor Presentation (February 2007)
32 slides from Transgene SA's investor presentation, February 2007
Slide 1: Corporate presentation
Corporate presentation transgene L’immunothérapie appliquée au traitement des cancers et des maladies infectieuses Immunotherapy to fight cancer and infectious diseases February 2007
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking statements, including statements regarding Transgene’s objectives for progress in its clinical trials and product candidate development. Statements that are not historical facts are based on the Company's current expectations, beli
Slide 3: Transgene's Strategy: Developing therapeutic vaccines to treat cancer and infectious diseases
Transgene’s Strategy: Developing therapeutic vaccines to treat cancer and infectious diseases Developing therapeutic vaccines and products in specific indications and partnering with pharmaceutical companies for later stage development. Included in our near term objectives are partnering deals for:
Slide 4: Transgene's Profile
Transgene’s Profile Financial data: Market capitalization = € 210 million at January 31, 2007 Cash end of September 2006 = € 25.1 million Warrants exercised in July 2006: € 14.3 million (76% exercised) Estimated 2006 burn rate = € 22 million Shareholders: Public Mérieux Alliance Group 46,1% 52,6% Fr
Slide 5: Sites
Sites Strasbourg (headquarters) Research Process development Clinical development Illkirch Biomanufacturing Kensington Clinical development U.S. Lyon Infectious diseases research 5 transgene
Slide 6: Substantial Pipeline at Key Turning Point
Substantial Pipeline at Key Turning Point Drug Candidate Indication Preclinical Phase I Phase II Phase III New Drug Current Status Application TG 4001 Prevention of Phase IIb (MVA –HPV-IL2) Cervical completed Q2 2006 Cancer TG 4010 Non-Small Phase II b interim (MVA- MUC1-IL2) Cell results Q3 2007 Lu
Slide 7: TG 4001 (MVA-HPV-IL2)
TG 4001 (MVA-HPV-IL2) 7 transgene
Slide 8: TG 4001 (MVA-HPV-IL2) Treating Precancerous Cervical Lesions
TG 4001 (MVA-HPV-IL2) Treating Precancerous Cervical Lesions Product: Antigen-specific therapeutic vaccine derived from Modified Vaccinia Ankara (MVA) poxvirus containing sequences encoding HPV16 E6/E7 antigens and the cytokine interleukin-2 (IL2). Target: Prevention of cervical cancer by treating p
Slide 9: TG 4001 (MVA-HPV-IL2) Positioning
TG 4001 (MVA-HPV-IL2) Positioning HPV Infection Silent Infection GlaxoSmithKline - Cervarix Merck - Gardasil TG 4001 CIN 2/3 Average age = 35 years Prevention Invasive cancer 5 10 15 20 25 30 35 40 45 years 9 transgene
Slide 10: Prevalency of different HPV Genotypes in Europe + USA for CIN 2/3
Prevalency of different HPV Genotypes in (Europe + USA) for CIN 2/3 CIN2/3 100 Others HPV16-like 50 average= 80.9% HPV16 average= 0 50.8% 0 38 00 87 02 =5 =1 =4 ,3 ,2 N =4 =1 N N N N Clifford, 2003 Meta-analysis Padilla, 2003 Becker,1994 Schiffman, 1993 Roda Husman, 1994 52% EU, 19% Latin America Al
Slide 11: CIN2/3 Existing Therapy: Cone Biopsy
CIN2/3 Existing Therapy: Cone Biopsy Surgical procedure under local or general anesthetic in hospital. Efficacy of about 53 % (considering 37 % relapse after 2 years for HPV16 CIN 2/3 lesions). Associated with complications: Bleeding in 3.5 - 5% of cases (International Agency for Research on Cancer)
Slide 12: Phase II Study: Patients
Phase II Study: Patients 21 women received 3 injections: Mean age: 34 years [25 – 44] Biopsy-proven CIN2/3 • Central histological reading: 6 CIN2 and 15 CIN3 Lesions entirely visualized by colposcopy HPV16 detected by PCR on biopsy No multi-infection with HPV18, HPV31 or HPV33 12 transgene
Slide 13: Phase II Study: 6 Months Efficacy Results
Phase II Study: 6 Months Efficacy Results Clinical response: 10 women had no CIN2/3 8 women had no LEEP because of normal colposcopy with normal cytology 2 women had CIN1 lesions: • 1 related to HPV45 and 1 related to HPV58/52 Virological response: All 10 women with no CIN2/3 had no HPV16 mRNA detec
Slide 14: Phase II Study: 12 Months Efficacy Results
Phase II Study: 12 months Efficacy Results M12 visit to be done for the 8 women with no LEEP at M6 7 patients reached M12 showing: No CIN2/3 relapse No HPV16 persistence or re-infection 1 woman was lost to follow-up after M6 14 transgene
Slide 15: Conclusion: Proof-of-Concept of Therapeutic Vaccination
Conclusion: Proof-of-Concept of Therapeutic Vaccination Therapeutic vaccination with TG4001 is feasible and safe in CIN2/3 women TG4001 can avoid around 50% of cone biopsies in women with HPV16-related CIN2/3 For patients who had a clinical response at M6: No CIN2/3 relapse at M12 No HPV16 persisten
Slide 16: TG 4010 (MVA-MUC1-IL2)
TG 4010 (MVA-MUC1-IL2) 16 transgene
Slide 17: TG 4010 (MVA-MUC1-IL2) in Non Small Cell Lung Cancer (NSCLC)
TG 4010 (MVA-MUC1-IL2) in Non Small Cell Lung Cancer (NSCLC) Product: Antigen-specific therapeutic vaccine derived from Modified Vaccinia Ankara (MVA) poxvirus containing the MUC1 antigen and the cytokine interleukin-2 (IL2). Target: NSCLC: MUC1 is overexpressed in 60% of NSCLC patients First line t
Slide 18: Positive TG 4010 (MVA-MUC1-IL2) Phase IIa Results
Positive TG 4010 (MVA-MUC1-IL2) Phase IIa Results Clear clinical benefit from the combination therapy as compared to the standard cisplatin/vinorelbine chemotherapy 35 evaluable patients # patients Response rate (%) Partial responses 13/35 37% Stable disease 12/35 34% Clinical benefit 25/35 71% 1-ye
Slide 19: TG 4010 in NSCLC: Controlled Phase IIb Protocol
TG 4010 (MVA-MUC1-IL2) in NSCLC: Controlled Phase IIb Protocol NSCLC, stage IIIB / IV (ie locally advanced / metastatic patients). Randomized, open label, multicenter study. Primary objective: to assess the efficacy of TG4010 combined with chemotherapy in comparison with chemotherapy alone. Efficacy
Slide 20: TG 4010 in NSCLC: Controlled Phase IIb
TG 4010 (MVA-MUC1-IL2) in NSCLC: Controlled Phase IIb Recruitment expected to be completed by early 2007 with first interim results due in Q3 2007. Adaptive design with Data & Safety Monitoring Board for Phase III trial as from March 2007 2005 2006 2007 2008 2009 2010 2011 2012 140 patients 650 pati
Slide 21: TG 1042 (Ad-IFNγ)
TG 1042 (Ad-IFNγ) 21 transgene
Slide 22: TG 1042 (Ad-IFNγ) in Cutaneous Lymphoma
TG 1042 (Ad-IFNγ) in Cutaneous Lymphoma Product: adenoviral vector containing the gene for the human interferon gamma cytokine. Target: cutaneous lymphoma (a skin malignancy), either T-cell or B-cell. Other cancer indications are under evaluation. Potential market: Cutaneous B-Cell Lymphoma (CBCL).
Slide 23: Positive TG 1042 Phase I/II Results in Cutaneous Lymphoma
Positive TG 1042 Phase I/II Results in Cutaneous Lymphoma Open-label multicenter, dose-escalation phase I/II trial with 39 patients (31 evaluable) with relapsing primary cutaneous T-cell or B-cell lymphoma. Repeated monthly cycles of 3 intratumoral injections. Complete Partial Total Evaluable Respon
Slide 24: TG 1042 (Ad-IFNγ) Current Status and Future Direction
TG 1042 (Ad-IFNγ) Current Status and Future Direction Pivotal Phase II trial: Open label, multicenter, two-step trial 41 patients with relapsing CBCL following radiotherapy in the US and Europe. Patient recruitment planned to start Q1 2007. Results expected early 2008. Commercial launch expected in
Slide 25: TG 4040 (MVA-HCV)
TG 4040 (MVA-HCV) 25 transgene
Slide 26: TG 4040 (MVA-HCV): Therapeutic Vaccine for Hepatitis C Chronic Carriers
TG 4040 (MVA-HCV): Therapeutic Vaccine for Hepatitis C Chronic Carriers Product: Antigen-specific therapeutic vaccine derived from Modified Vaccinia Ankara (MVA) poxvirus containing sequences encoding non-structural proteins (NS3, NS4 & NS5b) of the hepatitis C virus. Target: Chronic hepatitis C inf
Slide 27: NCI Collaboration
NCI Collaboration 27 transgene
Slide 28: NCI / Dr. Rosenberg Collaboration in Melanoma
NCI / Dr. Rosenberg Collaboration in Melanoma Initiation of a CRADA with Dr. S. Rosenberg, Chief of Surgery Branch at the NCI. Objective is to demonstrate synergistic effect of a therapeutic vaccine encoding gp100 and MART-1 following a lymphodepleting non-myeloablative regimen used for Adoptive Cel
Slide 29: Conclusion
Conclusion 29 transgene
Slide 30: 2006 / early 2007 Milestones
2006 / early 2007 Milestones TG 4001: Objective of concluding strategic out-licensing partnership. TG 4010: Planned completion of enrolment in the Phase IIb clinical study in NSCLC (Q1 2007). TG 1042 (Ad-IFNγ): Initiation of a Pivotal Phase II trial in the U.S. and Europe in cutaneous B-cell lymphom
Slide 31: Transgene's 2007 objective: Thank you for your attention
Transgene’s 2007 objective: Prepare Phase III trials supportive of BLA filings for its 2 most advanced products Thank you for your attention 31 transgene
Slide 32: Transgene contact details
11, rue de Molsheim 67082 Strasbourg Cedex France Contacts Transgene Tél. : + 33 (0) 3 88 27 91 21 Philippe Archinard, CEO Fax. : + 33 (0) 3 88 27 91 11 Philippe Poncet, CFO www.transgene.fr +33 3 88 27 91 00 32